Hosseini Seyed Ahmad, Zahrooni Nazanin, Ahmadzadeh Ahmad, Ahmadiangali Kambiz, Assarehzadegan Mohammad-Ali
Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Nutrition, Faculty of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Psychol Res Behav Manag. 2020 Feb 20;13:151-159. doi: 10.2147/PRBM.S241431. eCollection 2020.
Survival rates among breast cancer patients and the number of patients living with treatment side effects have improved, leading to increased focus on quality of life (QOL). The objective of this study was to determine the efficacy of CoQ on QOL scores among breast cancer patients in Iranian undergoing tamoxifen therapy.
Thirty breast cancer patients were randomized into two groups. The first group received 100 mg CoQ, and the second group took fplacebo once a day for 8 weeks. QOL was evaluated by a standard QOL questionnaire and a specific questionnaire on QOL of breast cancer patients at baseline and the end of the study. Also, physical activity of patients was assessed with the IPAQ questionnaire and dietary intake determined by a 3-day dietary record.
The data of 30 subjects were analyzed. According to QOL C30 data, CoQ led to a significant increase in physical functioning (=0.029), emotional functioning (=0.031), and cognitive functioning (=0.023) compared to placebo. Symptom scales revealed a notable reduction in appetite loss in the first group (=0.01). Global health status showed no significant changes in either study arm. On the QOL BR23, progress in functions and decline in symptoms were not statistically significant. Arm symptoms showed significant reduction (=0.022) in patients that received placebo.
This trial indicates that CoQ supplementation has effects in ameliorating some dimensions of QOL in breast cancer patients. To generalize the results, larger and longer intervention studies are needed.
IRCT2015042021874N1.
乳腺癌患者的生存率以及伴有治疗副作用的患者数量均有所改善，这使得人们对生活质量（QOL）的关注度日益提高。本研究的目的是确定辅酶Q（CoQ）对接受他莫昔芬治疗的伊朗乳腺癌患者生活质量评分的疗效。
30名乳腺癌患者被随机分为两组。第一组每天服用100毫克辅酶Q，第二组服用安慰剂，为期8周。在基线和研究结束时，通过标准生活质量问卷和乳腺癌患者生活质量专用问卷对生活质量进行评估。此外，使用国际体力活动问卷（IPAQ）评估患者的体力活动情况，并通过3天饮食记录确定饮食摄入量。
对30名受试者的数据进行了分析。根据生活质量核心问卷（QOL C30）数据，与安慰剂相比，辅酶Q使身体功能（P = 0.029）、情绪功能（P = 0.031）和认知功能（P = 0.023）有显著提高。症状量表显示，第一组食欲减退明显减少（P = 0.01）。全球健康状况在两个研究组中均无显著变化。在乳腺癌特异性生活质量问卷（QOL BR23）上，功能改善和症状减轻在统计学上无显著意义。接受安慰剂的患者手臂症状显著减轻（P = 0.022）。
本试验表明，补充辅酶Q对改善乳腺癌患者生活质量的某些方面有效果。为推广这些结果，需要进行更大规模且更长时间的干预研究。
IRCT2015042021874N1
